Radiopharm Theranostics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Radiopharm Theranostics Limited's Form 20-F filing for the fiscal year ended June 30, 2026, highlights significant operating losses and raises substantial doubt about its ability to continue as a going concern, despite ongoing research and development activities and capital raising efforts.
NASDAQ
Radiopharm Theranostics Limited filed an amendment to its annual report, updating its intellectual property portfolio and board meeting attendance for the fiscal year ended June 30, 2025.
NASDAQ
Radiopharm Theranostics reported a reduced comprehensive loss in fiscal 2025, driven by increased revenue and R&D tax incentives, while advancing multiple radiopharmaceutical drug candidates through clinical trials.